Substance / Medication

Inotersen

Overview

Active Ingredient
inotersen
RxNorm CUI
2099289

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Real-life experience with inotersen in hereditary transthyretin amyloidosis with late-onset phenotype: Data from an early-access program in Italy.
Luigetti Marco, Antonini Giovanni, Di Paolantonio Andrea et al. · Eur J Neurol · 2022
PMID: 35289020ObservationalFull text (PMC)
Indirect treatment comparison of the efficacy of patisiran and inotersen for hereditary transthyretin-mediated amyloidosis with polyneuropathy.
Gorevic Peter, Franklin Jaclyn, Chen Jihong et al. · Expert Opin Pharmacother · 2021
PMID: 32892660Observational
mNIS+7 and lower limb function in inotersen treatment of hereditary transthyretin-mediated amyloidosis.
Dyck P James B, Kincaid John C, Wiesman Janice F et al. · Muscle Nerve · 2020
PMID: 32654212ObservationalFull text (PMC)
Neuropathy symptom and change: Inotersen treatment of hereditary transthyretin amyloidosis.
Dyck P James B, Coelho Teresa, Waddington Cruz Marcia et al. · Muscle Nerve · 2020
PMID: 32654156ObservationalFull text (PMC)
Focal Segmental Glomerulosclerosis Complicating Therapy With Inotersen, an Antisense Oligonucleotide Inhibitor: A Case Report.
Law Steven, Arnold Julia, Rauf Muhammad U et al. · Am J Kidney Dis · 2023
PMID: 36228827Case Report
A case of severe increase of liver enzymes in a ATTRv patient after one year of inotersen treatment.
Severi Daniele, Palumbo Giovanni, Spina Emanuele et al. · Neurol Sci · 2023
PMID: 36576645Case ReportFull text (PMC)
Inotersen and severe thrombocytopenia: 2 case reports and review.
Domínguez Senín Loreto, Borrachero Garro Cristina, Sánchez Gómez Ernesto et al. · Int J Clin Pharmacol Ther · 2022
PMID: 35343431Case Report

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Inotersen (substance)
SNOMED CT
782581008
UMLS CUI
C4731850
RxNorm CUI
2099289

Clinical Data

This intervention maps to 1 entities in the Healos knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.